PUMA BIOTECHNOLOGY Business Summary

Puma Biotechnology, Inc. (PBYI) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of precision oncology therapeutics. The company generates revenue primarily through net product sales of NERLYNX (neratinib), an oral tyrosine kinase inhibitor approved for the extended adjuvant treatment of HER2-positive early-stage breast cancer and for metastatic cases in combination with capecitabine. Revenue streams are further diversified by royalty payments from international sub-licensing partners who market NERLYNX in global territories. Puma’s business segments are bifurcated into its commercial operations and its clinical development pipeline, which is currently centered on alisertib, a selective aurora kinase A inhibitor being evaluated for small cell lung cancer and HER2-negative, HR-positive breast cancer. Within the competitive landscape, Puma contends with oncology-focused peers such as Exelixis, ADMA Biologics, and CytomX Therapeutics. The company distinguishes itself as a rare profitable small-cap biotech, maintaining a lean operational structure while transitioning from a single-product firm to a diversified oncology platform. Leadership is spearheaded by Founder, Chairman, and CEO Alan H. Auerbach, who established the company in 2010 following the $1 billion acquisition of his previous venture, Cougar Biotechnology, by Johnson & Johnson. Auerbach’s pedigree includes a background as a senior research analyst at Wells Fargo Securities, specializing in oncology due diligence. The executive team includes Chief Financial Officer Maximo F. Nougues, formerly of Getinge AB and Boston Scientific, and Douglas Hunt, who serves as Senior Vice President of Regulatory Affairs and interim Chief Scientific Officer. Other key officers include Chief Commercial Officer Steven Lo and Senior Vice President of Marketing Heather J. Blaber. The company’s strategic direction is supported by a board of directors featuring industry veterans like Troy E. Wilson (CEO of Kura Oncology) and Brian Stuglik (former CEO of Verastem). Notable institutional investors include Invesco Ltd., Mackenzie Financial Corp, and Bridgeway Capital Management, reflecting sustained institutional confidence in the company’s commercial execution and clinical pipeline.